首页> 外文期刊>Advanced Functional Materials >The Neuroprotective Effect of MicroRNA-22-3p Modified Tetrahedral Framework Nucleic Acids on Damaged Retinal Neurons Via TrkB/BDNF Signaling Pathway
【24h】

The Neuroprotective Effect of MicroRNA-22-3p Modified Tetrahedral Framework Nucleic Acids on Damaged Retinal Neurons Via TrkB/BDNF Signaling Pathway

机译:MicroRNA-22-3P改性四面体骨架核酸在TRKB / BDNF信号通路损伤视网膜神经元的神经保护作用

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Glaucoma is the world's leading irreversible cause of blindness. It is characterized by progressive retinal ganglion cells (RGCs) loss and axon damage, and there is no effective prevention or treatment so far. In this study, tetrahedral frame nucleic acids (tFNAs) with various biological functions are selected as the carrier, and microRNA-22-3p (miR-22) are modified by attaching them onto tFNAs to synthesize a novel DNA nanocomplex (tFNAs-miR22). Relevant results show that tFNAs can efficiently transfer miR-22 into damaged retinal neurons to impose a neuroprotective effect on glaucoma. More interestingly, a certain synergism between tFNAs and miR-22 is shown. tFNAs-miR22 can selectively activate tyrosine kinase receptor B (TrkB) and regulate the TrkB-brain-derived growth factor (BDNF) signaling pathway to restore the expression of BDNF on the models of N-methyl-D-aspartate (NMDA)-induced glaucoma in vivo and in vitro, thus exerting the neuroprotective effect on retinal neurons. This study shows the successfully establishment of a simple but effective delivery system of microRNAs associated with glaucoma treatment, which may be a promising neuroprotective agent for future treatment of this optic neurodegenerative disease.
机译:青光眼是世界领先的不可逆转的失明原因。它的特征在于渐进式视网膜神经节细胞(RGCS)损失和轴突损伤,目前没有有效的预防或治疗。在该研究中,选择具有各种生物功能的四面体框架核酸(TFNA)作为载体,通过将它们连接到TFNA上以合成新型DNA纳米键(TFNAS-MiR22)来修饰MicroRNA-22-3P(miR-22)。 。相关结果表明,TFNA可以有效地将MIR-22转移到受损的视网膜神经元中以对青光眼施加神经保护作用。更有意义地,显示了TFNA和MIR-22之间的某种协同作用。 TFNAS-MIR22可以选择性地激活酪氨酸激酶受体B(TRKB)并调节TRKB-脑衍生的生长因子(BDNF)信号通路,以恢复BDNF在N-甲基-D-天冬氨酸(NMDA)的模型上的表达 - 诱导的葡萄糖在体内和体外,从而施加对视网膜神经元的神经保护作用。本研究表明,成功建立了与青光眼处理相关的简单但有效的微小携带系统,这可能是未来治疗这种视神经性疾病的有前途的神经保护剂。

著录项

  • 来源
    《Advanced Functional Materials》 |2021年第36期|2104141.1-2104141.13|共13页
  • 作者单位

    Sichuan Univ State Key Lab Oral Dis Natl Clin Res Ctr Oral Dis West China Hosp Stomatol Chengdu 610041 Peoples R China;

    Sichuan Univ West China Hosp Dept Ophthalmol Chengdu 610041 Peoples R China;

    Sichuan Univ West China Hosp Dept Ophthalmol Chengdu 610041 Peoples R China;

    Sichuan Univ State Key Lab Oral Dis Natl Clin Res Ctr Oral Dis West China Hosp Stomatol Chengdu 610041 Peoples R China;

    Sichuan Univ State Key Lab Oral Dis Natl Clin Res Ctr Oral Dis West China Hosp Stomatol Chengdu 610041 Peoples R China;

    Sichuan Univ State Key Lab Oral Dis Natl Clin Res Ctr Oral Dis West China Hosp Stomatol Chengdu 610041 Peoples R China;

    Sichuan Univ State Key Lab Oral Dis Natl Clin Res Ctr Oral Dis West China Hosp Stomatol Chengdu 610041 Peoples R China;

    Sichuan Univ State Key Lab Oral Dis Natl Clin Res Ctr Oral Dis West China Hosp Stomatol Chengdu 610041 Peoples R China;

    Sichuan Univ West China Hosp Dept Ophthalmol Chengdu 610041 Peoples R China;

    Sichuan Univ State Key Lab Oral Dis Natl Clin Res Ctr Oral Dis West China Hosp Stomatol Chengdu 610041 Peoples R China|Sichuan Univ Coll Biomed Engn Chengdu 610041 Peoples R China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    brain-derived neurotrophic factor; glaucoma; microRNA-22-3p; neuroprotection; tetrahedral frame nucleic acids;

    机译:脑源性神经营养因子;青光眼;microRNA-22-3P;神经保护;四面体框架核酸;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号